Last updated on February 2019

Improving Pregnancy Outcomes With Progesterone

Brief description of study

This is a phase III, double-masked, placebo-controlled, randomized controlled trial taking place in Zambia.

Detailed Study Description

Weekly intramuscular injections of 250mg 17-alpha hydroxyprogesterone caproate (17P) or indistinguishable placebo will be randomly allocated in a 1:1 ratio started between 16-24 weeks gestation and administered weekly thereafter until 36 6/7 gestational weeks, stillbirth, or delivery, whichever is sooner. Individual participants will be followed from enrollment (prior to 24 weeks gestation) through 42 days postpartum.

Clinical Study Identifier: NCT03297216

Find a site near you

Start Over